XML 51 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Commitments & Contingencies and Key License Agreements - Additional Information (Details)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Apr. 30, 2019
USD ($)
Apr. 30, 2018
USD ($)
Apr. 30, 2016
shares
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
product
Sep. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Jan. 01, 2019
USD ($)
Long-term Purchase Commitment [Line Items]                  
Lease cost       $ 569 $ 479 $ 1,758 $ 1,584    
Operating lease right-of-use assets - non-current       2,662   2,662   $ 3,806  
Operating lease liability       2,865   $ 2,865   4,055  
Right-of-use asset obtained in exchange for operating lease liability             $ 4,600    
Licensors | product           2      
Deferrals and contributions       8,400   $ 8,400   8,700  
Office equipment                  
Long-term Purchase Commitment [Line Items]                  
Operating lease right-of-use assets - non-current       300   300   400  
Office and research facilities                  
Long-term Purchase Commitment [Line Items]                  
Operating lease right-of-use assets - non-current       $ 2,300   2,300   $ 3,400  
ImmunGene                  
Long-term Purchase Commitment [Line Items]                  
Potential payments based on achievement of regulatory milestones           26,100      
Asset purchase agreement, upfront payment $ 2,800                
Potential payments based on additional achievements of regulatory milestones           5,000      
MD Anderson                  
Long-term Purchase Commitment [Line Items]                  
Potential payments based on achievement of regulatory milestones           6,000      
Potential payments based on achievement of sales milestones           24,000      
Payment Of Upfront Fee   $ 500              
SPI-2012                  
Long-term Purchase Commitment [Line Items]                  
Issuance (shares) | shares     318,750            
Potential payments based on achievement of regulatory milestones           10,000      
Potential payments based on achievement of sales milestones           120,000      
Poziotinib | Licensing Agreements                  
Long-term Purchase Commitment [Line Items]                  
Potential payments based on achievement of regulatory milestones           33,000      
Potential payments based on achievement of sales milestones           $ 325,000      
ASU 2016-02                  
Long-term Purchase Commitment [Line Items]                  
Operating lease right-of-use assets - non-current                 $ 4,200
Operating lease liability                 $ 4,200
Minimum                  
Long-term Purchase Commitment [Line Items]                  
Remaining lease term       1 year   1 year      
Maximum                  
Long-term Purchase Commitment [Line Items]                  
Remaining lease term       4 years   4 years